[{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KO-539","moa":"Menin-MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"KO-539","moa":"Menin-MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"KO-539","moa":"Menin-MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"KO-539","moa":"Menin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"KO-539","moa":"Menin-MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Kura Oncology \/ EcoR1 Capital","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ EcoR1 Capital"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ BofA Securities"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Kura Oncology \/ AstraZeneca"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Leukemia & Lymphoma Society","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kura Oncology \/ Leukemia & Lymphoma Society","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Leukemia & Lymphoma Society"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kura Oncology \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Ziftomenib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.

                          Brand Name : KO-539

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 08, 2024

                          Lead Product(s) : Ziftomenib,Imatinib Mesylate

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated for the treatment of patients with relapsed/refractory NPM1-mutant acute myeloid leukemia (AML).

                          Brand Name : KO-539

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 14, 2024

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KO-539 (ziftomenib) is a menin-KMT2A/MLL inhibitor that has received Breakthrough Therapy Designation from the FDA for treating relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML).

                          Brand Name : KO-539

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 22, 2024

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KO-539 (ziftomenib) is a potent and selective a menin-MLL(KMT2A) inhibitor, which is being evaluated in phase 1 clinical trials in patients with NPM1-mutant & KMT2A-rearranged acute myeloid leukemia.

                          Brand Name : KO-539

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 26, 2024

                          Lead Product(s) : Ziftomenib,Gilteritinib Fumarate,Fludarabine Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : AstraZeneca

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : KO-539 (ziftomenib) is a potent and selective a menin-MLL(KMT2A) inhibitor, which is being evaluated in phase 2 clinical trials in patients with NPM1-mutant & KMT2A-rearranged acute myeloid leukemia.

                          Brand Name : KO-539

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 30, 2024

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Kura will use proceeds for R&D of its clinical-stage candidates, including KO-539 (ziftomenib), an oral menin-KMT2A inhibitor for treating Acute Myeloid Leukemia.

                          Brand Name : KO-539

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 24, 2024

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : EcoR1 Capital

                          Deal Size : $150.0 million

                          Deal Type : Private Placement

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration aims to evaluate Kura’s menin inhibitor, KO-539 (ziftomenib), in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-rearranged or NPM1-mutant acute leukemia.

                          Brand Name : KO-539

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 08, 2023

                          Lead Product(s) : Ziftomenib,Fludarabine Phosphate,Idarubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Leukemia & Lymphoma Society

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The net proceeds will be used to advance company's pipeline of product candidates, including continued development of KO-539 (ziftomenib), a potent and selective small molecule inhibitor of the menin-MLL protein-protein interaction, tipifarnib and KO-280...

                          Brand Name : KO-539

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 14, 2023

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : BofA Securities

                          Deal Size : $100.0 million

                          Deal Type : Public Offering

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The net proceeds will be used for the development of KO-539 (ziftomenib), a potent and selective inhibitor, being developed in combination with Xospata (gilteritinib), an inhibitor of FLT3, for the treatment of NPM1-mutated acute myeloid leukemia.

                          Brand Name : KO-539

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 14, 2023

                          Lead Product(s) : Ziftomenib,Gilteritinib Fumarate

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : BofA Securities

                          Deal Size : $100.0 million

                          Deal Type : Public Offering

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The net proceeds will be used to advance company's pipeline of product candidates, including continued development of KO-539 (ziftomenib), a potent and selective small molecule inhibitor of the menin-MLL protein-protein interaction, tipifarnib and KO-280...

                          Brand Name : KO-539

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 13, 2023

                          Lead Product(s) : Ziftomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : BofA Securities

                          Deal Size : Undisclosed

                          Deal Type : Public Offering

                          blank